Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Individualised Lu-177-DOTATATE treatment of neuroendocrine tumours based on kidney dosimetry

Artikel i vetenskaplig tidskrift
Författare A. Sundlov
K. Sjogreen-Gleisner
J. Svensson
M. Ljungberg
T. Olsson
Peter Bernhardt
J. Tennvall
Publicerad i European Journal of Nuclear Medicine and Molecular Imaging
Volym 44
Nummer/häfte 9
Sidor 1480-1489
ISSN 1619-7070
Publiceringsår 2017
Publicerad vid Institutionen för kliniska vetenskaper, sektionen för onkologi, radiofysik, radiologi och urologi, Avdelningen för radiofysik
Sidor 1480-1489
Språk English
Länkar doi.org/10.1007/s00259-017-3678-4
Ämnesord Lu-177-DOTATATE, Neuroendocrine, Dosimetry, PRRT, Renal function, receptor radionuclide therapy, radiolabeled somatostatin analog, toxicity, y-90-dotatoc, octreotate, survival, cancers, Radiology, Nuclear Medicine & Medical Imaging
Ämneskategorier Klinisk medicin

Sammanfattning

Purpose To present data from an interim analysis of a Phase II trial designed to determine the feasibility, safety, and efficacy of individualising treatment based on renal dosimetry, by giving as many cycles as possible within a maximum renal biologically effective dose (BED). Method Treatment was given with repeated cycles of 7.4 GBq 177Lu-DOTATATE at 8-12-week intervals. Detailed dosimetry was performed in all patients after each cycle using a hybrid method (SPECT + planar imaging). All patients received treatment up to a renal BED of 27 +/- 2 Gy (alpha/beta = 2.6 Gy) (Step 1). Selected patients were offered further treatment up to a renal BED of 40 +/- 2 Gy (Step 2). Renal function was followed by estimation and measurement of the glomerular filtration rate (GFR). Results Fifty-one patients were included in the present analysis. Among the patients who received treatment as planned, the median number of cycles in Step 1 was 5 (range 3-7), and for those who completed Step 2 it was 7 (range 5-8); 73% were able to receive >4 cycles. Although GFR decreased in most patients after the completion of treatment, no grade 3-4 toxicity was observed. Patients with a reduced baseline GFR seemed to have an increased risk of GFR decline. Five patients received treatment in Step 2, none of whom exhibited a significant reduction in renal function. Conclusions Individualising PRRT using renal dosimetry seems feasible and safe and leads to an increased number of cycles in the majority of patients. The trial will continue as planned.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?